EA202192757A1 - Способ лечения опухолей - Google Patents

Способ лечения опухолей

Info

Publication number
EA202192757A1
EA202192757A1 EA202192757A EA202192757A EA202192757A1 EA 202192757 A1 EA202192757 A1 EA 202192757A1 EA 202192757 A EA202192757 A EA 202192757A EA 202192757 A EA202192757 A EA 202192757A EA 202192757 A1 EA202192757 A1 EA 202192757A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tumor treatment
effect
tumors
epoxytiglienone
abscopal
Prior art date
Application number
EA202192757A
Other languages
English (en)
Russian (ru)
Inventor
Виктория Энн Гордон
Пол Уоррен Реддел
Глен Мэтью Бойль
Джейсон Кингсли Каллен
Питер Гордон Парсонс
Original Assignee
Кьюбиотикс Пти Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019901280A external-priority patent/AU2019901280A0/en
Application filed by Кьюбиотикс Пти Лтд filed Critical Кьюбиотикс Пти Лтд
Publication of EA202192757A1 publication Critical patent/EA202192757A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA202192757A 2019-04-12 2020-04-09 Способ лечения опухолей EA202192757A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2019901280A AU2019901280A0 (en) 2019-04-12 Method of Treatment
PCT/AU2020/050360 WO2020206504A1 (en) 2019-04-12 2020-04-09 Method of treating tumours

Publications (1)

Publication Number Publication Date
EA202192757A1 true EA202192757A1 (ru) 2022-02-11

Family

ID=72752169

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192757A EA202192757A1 (ru) 2019-04-12 2020-04-09 Способ лечения опухолей

Country Status (26)

Country Link
US (1) US12226391B2 (cg-RX-API-DMAC7.html)
EP (1) EP3952858B1 (cg-RX-API-DMAC7.html)
JP (2) JP7900152B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210152531A (cg-RX-API-DMAC7.html)
CN (1) CN113924091A (cg-RX-API-DMAC7.html)
AU (1) AU2020256847B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020253A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136216C (cg-RX-API-DMAC7.html)
DK (1) DK3952858T3 (cg-RX-API-DMAC7.html)
EA (1) EA202192757A1 (cg-RX-API-DMAC7.html)
ES (1) ES3063750T3 (cg-RX-API-DMAC7.html)
FI (1) FI3952858T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260232T1 (cg-RX-API-DMAC7.html)
IL (1) IL287210B2 (cg-RX-API-DMAC7.html)
LT (1) LT3952858T (cg-RX-API-DMAC7.html)
MX (1) MX2021012449A (cg-RX-API-DMAC7.html)
MY (1) MY208979A (cg-RX-API-DMAC7.html)
PL (1) PL3952858T3 (cg-RX-API-DMAC7.html)
PT (1) PT3952858T (cg-RX-API-DMAC7.html)
RS (1) RS67777B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110599RA (cg-RX-API-DMAC7.html)
SI (1) SI3952858T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600066T1 (cg-RX-API-DMAC7.html)
UA (1) UA129840C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020206504A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202108677B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1971588T3 (da) * 2005-12-23 2012-10-22 Qbiotics Ltd Tiglien-3-onderivater
JP7013753B2 (ja) * 2017-09-15 2022-02-01 株式会社三洋物産 遊技機
BR112021024716A2 (pt) 2019-06-19 2022-02-08 QBiotics Pty Ltd Ruptura de biofilme
CN118451065A (zh) * 2021-12-21 2024-08-06 Q生物股份有限公司 结晶中间体
EP4638430A4 (en) * 2022-12-21 2026-07-01 QBiotics Pty Ltd CRYSTALLINE FORMS AND THEIR PRODUCTION PROCESSES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1971588T3 (da) * 2005-12-23 2012-10-22 Qbiotics Ltd Tiglien-3-onderivater
PT2986615T (pt) 2013-04-18 2019-03-22 Qbiotics Ltd Métodos e composições para a cicatrização de feridas
EP3490547A4 (en) * 2016-07-28 2020-04-01 QBiotics Pty Ltd TREATMENT METHOD
SG11201907891XA (en) * 2017-03-23 2019-09-27 QBiotics Pty Ltd Combination therapy for the treatment or prevention of tumours

Also Published As

Publication number Publication date
ZA202108677B (en) 2026-03-25
CA3136216A1 (en) 2020-10-15
SI3952858T1 (sl) 2026-04-30
WO2020206504A1 (en) 2020-10-15
AU2020256847A1 (en) 2021-11-11
IL287210B1 (en) 2025-03-01
UA129840C2 (uk) 2025-08-20
IL287210A (en) 2021-12-01
CN113924091A (zh) 2022-01-11
MY208979A (en) 2025-06-14
ES3063750T3 (en) 2026-04-20
FI3952858T3 (fi) 2026-02-18
US12226391B2 (en) 2025-02-18
RS67777B1 (sr) 2026-03-31
HRP20260232T1 (hr) 2026-03-27
SMT202600066T1 (it) 2026-03-09
LT3952858T (lt) 2026-04-10
US20220193023A1 (en) 2022-06-23
EP3952858A4 (en) 2022-05-25
SG11202110599RA (en) 2021-10-28
KR20210152531A (ko) 2021-12-15
EP3952858A1 (en) 2022-02-16
PT3952858T (pt) 2026-02-26
CA3136216C (en) 2024-01-16
AU2020256847B2 (en) 2025-05-15
MX2021012449A (es) 2021-11-12
IL287210B2 (en) 2025-07-01
EP3952858B1 (en) 2025-12-17
JP7900152B2 (ja) 2026-08-04
BR112021020253A2 (pt) 2021-12-07
JP2022528915A (ja) 2022-06-16
DK3952858T3 (da) 2026-02-23
PL3952858T3 (pl) 2026-03-30
JP2025060945A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
PH12019501896A1 (en) Therapeutic dendrimers
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
ZA201907225B (en) Treatment of her2 positive cancers
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MY189601A (en) Treatment of beta-thalassemia using actrii ligand traps
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
CY1125126T1 (el) Θεραπεια συνδυασμου αναστολεα βρωμοεπικρατειας και επιπλεον-τερματικης πρωτεϊνης
WO2019055880A3 (en) Method of administration and treatment
WO2020033838A3 (en) Treatment of egfr-mutant cancer
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
RU2012140185A (ru) Ингибирование ангиогенеза
MX2020009842A (es) Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido.
MX2020001856A (es) Terapia de combinacion para tratar el cancer con administracion intravenosa de un virus vaccinia ankara modificado (mva) recombinante y un anticuerpo.
EA202190403A1 (ru) Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство
JOP20200242A1 (ar) مركبات البلاديينوليد واستخداماتها
ZA202108677B (en) Method of treating tumours
MX382357B (es) Métodos y composiciones para tratar infecciones fúngicas cutáneas.
MX2025008524A (es) Métodos y composiciones para la terapia combinada
JOP20200124A1 (ar) طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
EA202092540A1 (ru) Комбинации для лечения рака
EA202190457A1 (ru) Конъюгаты для применения в способах лечения рака
EA201892631A1 (ru) Дигидротестостерон и производные и промоторы дигидротестостерона в лечении рака